title: Anti-Depressant Therapy Brightens the Outlook for Prostate Cancer Bone Metastases.
abstract: In this issue of Cancer Cell, Wu et al. identify MAOA as a key mediator of osteolytic bone responses that involve complex paracrine interactions between tumor cells, osteoblasts, and osteoclasts. Pharmacological inhibition of MAOA enzymatic activity effectively interrupted osteolysis and metastatic progression in preclinical models, suggesting a new treatment opportunity.
authors.affiliation: Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
authors.forename: Michael D
authors.initials: MD
authors.lastname: Nyquist
authors.affiliation: Divisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA; Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA 98195, USA. Electronic address: pnelson@fhcrc.org.
authors.forename: Peter S
authors.initials: PS
authors.lastname: Nelson
mesh_terms: D001859:Bone Neoplasms; D045744:Cell Line, Tumor; D006801:Humans; D008297:Male; D010006:Osteoblasts; D010010:Osteoclasts / Q000187:drug effects; D010014:Osteolysis; D011471:Prostatic Neoplasms